This is a routine compensation amendment with no material financial or operational implications. Monitor upcoming quarterly filings for any changes in cash burn or equity dilution from the new option and RSU grants.
Price Chart
Executive Summary
Akari Therapeutics amended its CEO's employment agreement, increasing annual base salary from $475,000 to $625,000 and the target bonus from 50% to 55% of base salary. The CEO also received a grant of options to purchase 174,000 ADSs and voluntarily elected to receive $62,500 of salary as RSUs in lieu of cash. This is a routine compensatory arrangement for the CEO, with no departure or financial results disclosed.
Key Facts
- CEO Abizer Gaslightwala's annual base salary increased from $475,000 to $625,000 effective August 18, 2026
- Target annual bonus increased from 50% to 50% to 55% of base salary, resulting in target annual base salary and bonus compensation of approximately $970,000
- Grant of options to purchase 174,000 ADSs under the 2023 Plan, vesting monthly over four years
- CEO voluntarily elected to receive $62,500 of base salary as RSUs in lieu of cash for 12 months
- No departure, resignation, or termination of any officer or director
- No financial statements or material financial data provided
Financial Impact
CEO base salary increase of $150,000 per year and target bonus increase to 55% of base salary; total target compensation approximately $970,000
Risk Factors
- Potential shareholder dilution if the 2023 Plan is amended to increase ADS reserves for the new options and RSUs
- No financial data or guidance provided to assess the impact on the company's financial position
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-045364 |
| Exhibit: ex10-1.htm | 0001493152-26-045364 |
| Document: 0001493152-26-045364-index-headers.html | 0001493152-26-045364 |
| Document: 0001493152-26-045364-index.html | 0001493152-26-045364 |
| Document: 0001493152-26-045364.txt | 0001493152-26-045364 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | DEF 14A | $8.72 | awaiting T+60 | — | $7.63 (−12.50%) |
Oct 1, 2026 25d ago | 8-K | $8.72 | awaiting T+60 | — | $7.63 (−12.50%) |
Aug 13, 2026 10w ago | 8-K | $7.54 | awaiting T+60 | — | $7.63 (+1.19%) |
Jul 14, 2026 15w ago | EFFECT | $13.42 $8.63 | ▲ +35.73% | ▲ +39.11% | $7.63 (+43.14%) |
Jul 8, 2026 15w ago | EFFECT | $14.21 $8.84 | ▼ −37.79% | ▼ −40.28% | $7.63 (−46.31%) |
Jul 2, 2026 16w ago | S-3 | $10.41 $9.81 | ▲ +5.76% | ▲ +9.33% | $7.63 (+26.71%) |
Jun 29, 2026 17w ago | Press Release | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $7.63 (−21.26%) |
Jun 26, 2026 17w ago | 8-K | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $7.63 (−21.26%) |
May 28, 2026 21w ago | Press Release | $22.05 $7.85 | ▼ −64.40% | ▼ −66.13% | $7.63 (−65.40%) |
May 22, 2026 22w ago | 8-K | $17.81 $7.90 | ▲ +55.64% | ▲ +58.37% | $7.63 (+57.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers